Meeting
2017 Genitourinary Cancers Symposium
A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Fatima Karzai
National Cancer Institute at the National Institutes of Health, Bethesda, MD
Fatima Karzai , Ravi Amrit Madan , Helen Owens , Amy Hankin , Anna Couvillon , Nicole D. Houston , Farhad Fakhrejahani , Marijo Bilusic , Marc Robert Theoret , Lisa M Cordes , Jane B. Trepel , Daniel C. Edelman , Paul S. Meltzer , James L. Gulley , William L. Dahut , Jung-min Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02484404
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 162)
DOI
10.1200/JCO.2017.35.6_suppl.162
Abstract #
162
Poster Bd #
F16
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Fatima Karzai
Poster
2022 ASCO Genitourinary Cancers Symposium
BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Benedito A. Carneiro
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II single-arm trial of niraparib in platinum-sensitive metastatic castration-resistant prostate cancer with DNA repair defects (PLATPARP).
First Author: Vivek Narayan
Poster
2021 Genitourinary Cancers Symposium
Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).
First Author: Fadi Taza